Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773980 | 0.89 | MAPK14 (0.79) | MAPK14SMO | |
| SCHEMBL3693867 | 0.87 | MAPK14 (0.79) | MAPK14SMO | |
| SCHEMBL3763344 | 0.86 | SMO (0.74) | MAPK14SMO | |
| SCHEMBL3769398 | 0.86 | MAPK14 (0.89) | MAPK14SMO | |
| SCHEMBL31510660 | 0.85 | SMO (1.00) | MAPK14SMO | |
| Methylamine SCHEMBL27817975 | 0.85 | MAPK14 (0.75) | MAPK14SMO | |
| SCHEMBL2354048 | 0.85 | MAPK14 (1.00) | MAPK14SMO | |
| SCHEMBL2351839 | 0.85 | SMO (0.77) | MAPK14SMO | |
| SCHEMBL2351834 | 0.84 | MAPK14 (1.00) | MAPK14SMO | |
| SCHEMBL2362631 | 0.84 | SMO (1.00) | MAPK14SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011095807-A1 | COMBINATIONS OF MEK AND HH INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-11 | — | — | WO | disclosed |
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| CN-101835752-A | Heterocyclic amides useful for the treatment of cancer and psoriasis | ASTRAZENECA AB | 2010-09-15 | — | — | CN | disclosed |
| EP-2188255-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | AstraZeneca AB (SE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009027746-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | SHH, GLI1, HRH4 | MAPK14 1705/4885SMO 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.